-

restor3d Announces Full Commercial Launch of Ossera™ AFX Ankle Fusion Cage System, Immediately Available in Both Standard and Made-to-Order Options

DURHAM, N.C.--(BUSINESS WIRE)--restor3d, a leader in 3D-printed, personalized orthopedic solutions, today announced the full commercial launch of the Ossera™ AFX Ankle Fusion Cage System, a comprehensive platform engineered to address complex ankle fusion cases and now available in both standard off-the-shelf and made-to-order configurations.

“We understand that every surgeon has unique preferences and approaches when it comes to patient care,” said Ken Gall, Chief Commercial Officer at restor3d. “That’s why we offer a comprehensive array of personalization options across our portfolio..."

Share

Following a successful limited market release over the past several months, restor3d has expanded the Ossera™ AFX portfolio to include a standardized implant offering in Cylinder, Dome, and Pill geometries. These geometries were developed through years of analysis of restor3d patient case data to optimize fit across a broad range of anatomies. Designed specifically for foot and ankle procedures, the system combines 3D-printed Titanium alloy implants, foot and ankle-specific reusable instrumentation, and TIDAL Technology™, restor3d’s proprietary porous architecture engineered to support osseointegration.

“The Ossera™ AFX System is a readily available, standardized solution to deal with critical bone defects and has superior mechanical and osseointegration properties compared to allograft,” said Christopher Kreulen, MD. “The foot and ankle specific instrumentation and robust selection of sizes have significantly changed my complex limb salvage practice.”

Ossera™ AFX is designed for rapid delivery, with sterile-packed implants and reusable instrumentation available immediately. The system’s thoughtful design, including cannulated reamers, flat cut guides, and lateral fibular relief across implant geometries, supports efficient, reproducible surgical workflows while providing intraoperative flexibility.

“We understand that every surgeon has unique preferences and approaches when it comes to patient care,” said Ken Gall, Chief Commercial Officer at restor3d. “That’s why we offer a comprehensive array of personalization options across our portfolio. Our goal is to ensure that every surgeon has access to the right tools to achieve the best possible outcomes.”

The Ossera™ AFX Ankle Fusion Cage System is launching to full-scale commercial distribution on February 6, 2026. To learn more about the system please visit https://www.restor3d.com/ossera-afx/

About restor3d, Inc.

restor3d is a world leader in 3D printed patient specific musculoskeletal implants and driven by the belief that every patient deserves personalized care. The company holds proprietary expertise and intellectual property in 3D printing of osseointegrative materials, AI-based planning and design automation tools, and digital health solutions to provide seamless data-backed care to optimize individual patient outcomes. Alongside its customers, restor3d is reimagining the musculoskeletal reconstruction landscape. More information is available at www.restor3d.com.

Forward-Looking Statements

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “future,” “believes,” “expects,” “may,” “will,” “should,” “potential,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations but are subject to known and unknown risks and uncertainties including, without limitation, distribution challenges, market trends and demand, product efficacy and safety concerns, product or raw material availability and other supply constraints. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results. The forward-looking statements included are made only as the date of this release. The company assumes no obligation to update any information or forward-looking statement contained herein, save for any information required to be disclosed by law.

Contacts

Jordan Wagner
Vice President of Marketing, restor3d
281-866-4988
jordan.wagner@restor3d.com

restor3d


Release Versions

Contacts

Jordan Wagner
Vice President of Marketing, restor3d
281-866-4988
jordan.wagner@restor3d.com

Social Media Profiles
More News From restor3d

restor3d Announces First Clinical Cases of the iTotal Identity™ CR 3DP Porous Fully Personalized Total Knee Replacement System

DURHAM, N.C.--(BUSINESS WIRE)--restor3d, a leader in 3D-printed, personalized orthopedic solutions, today announced the successful completion of the first clinical cases using the iTotal Identity™ CR 3DP Porous Fully Personalized Total Knee Replacement System. The inaugural procedure was performed by William J. Berghoff, MD, at Parkview Orthopedic Hospital in Fort Wayne, Indiana, marking a major milestone in the system’s limited market release and the next evolution of personalized knee arthrop...

restor3d Announces Strategic Investment Partnership with Partners Group to Accelerate Growth in Personalized Orthopedic Solutions

DURHAM, N.C.--(BUSINESS WIRE)--restor3d, a leader in technology-driven personalized orthopedic solutions, today announced a strategic investment partnership with Partners Group, one of the largest firms in the global private markets industry, acting on behalf of its clients. Under the agreement, Partners Group will acquire a significant minority stake in restor3d, marking the Company’s first institutional investment. As part of this transaction, restor3d has raised a total of $104 million, incl...

restor3d Announces Successful Limited Market Release of the Aeros™ Modular Stem Total Ankle System with Five Cases Performed on Day One

DURHAM, N.C.--(BUSINESS WIRE)--restor3d, a leader in 3D printed, personalized orthopedic implant care, proudly announces the successful limited market release of the Aeros™ Modular Stem Total Ankle System, with five cases performed on launch day, May 5, 2025, at OrthoCarolina by renowned foot and ankle specialists Dr. Kent Ellington and Aeros design team member, Dr. Samuel Ford. The Aeros Modular Stem, the latest addition to the Kinos Total Ankle family, represents the first and only anteriorly...
Back to Newsroom